Subscribe to RSS

DOI: 10.1055/a-0957-3067
Gastric mucosal devitalization (GMD): translation to a novel endoscopic metabolic therapy
TRIAL REGISTRATION: Single arm, interventional clinical trial NCT03526263 at clinicaltrials.govPublication History
submitted 14 May 2019
accepted after revision 27 May 2019
Publication Date:
25 November 2019 (online)

Abstract
Background and study aims The metabolic effects of bariatric surgery may partially result from removal of the gastric mucosa, an often underappreciated endocrine organ. Using argon plasma coagulation (APC), we may be able to selectively devitalize (ablate) the mucosa. The aim of this study was to identify the optimal tissue color that would correspond to selective gastric mucosal devitalization (GMD) using ex-vivo human stomach specimens.
Patients and methods Stomach specimens were obtained at sleeve gastrectomy. Prior to APC application, a submucosal fluid cushion was created. APC was then applied over a 2 × 2-cm area to the fundus and body, aiming for the three indicator colors (white, golden, brown). Pathological analysis was then performed independently and in a blinded fashion by two pathologists to determine the depth of mucosal and submucosal percent thermal injury and mucosal percent cell death.
Results Six patients were enrolled. There was a significant correlation between tissue color and mucosal percent thermal injury. The highest percent mucosal thermal injury was seen with brown (99.6 %, 95 % CI: 98.7, 100), followed by golden (92.5 %, 95 % CI: 85.5, 99.5), and then white (75.2 %, 95 % CI: 58.3, 92.1, P < 0.01). Submucosal thermal injury was seen in 88.9 % of the slides. Greater than minimal submucosal injury (> 10 % depth) was found significantly more with brown tissue color (91.6 %) than golden (75 %) or white (33.3 %, P < 0.05). However, 91.7 % of the entire sample set < 50 % injury.
Conclusion GMD is achievable using APC without thermal injury to muscularis propria. A golden color results in sufficient mucosal injury with only superficial injury to the submucosa.
-
References
- 1 Finkelstein EA, Trogdon JG, Cohen JW. et al. Annual medical spending attributable to obesity: payer-and service-specific estimates. Health Aff (Millwood) 2009; 28: w822-w831
- 2 Flegal KM, Carroll MD, Ogden CL. et al. Prevalence and trends in obesity among US adults, 1999 – 2008. JAMA 2010; 303: 235-241
- 3 Ng M, Fleming T, Robinson M. et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2014; 384: 766-781
- 4 Nguyen NT, Magno CP, Lane KT. et al. Association of hypertension, diabetes, dyslipidemia, and metabolic syndrome with obesity: findings from the National Health and Nutrition Examination Survey, 1999 to 2004. J Am Coll Surg 2008; 207: 928-934
- 5 English WJ, DeMaria EJ, Brethauer SA. et al. American Society for Metabolic and Bariatric Surgery estimation of metabolic and bariatric procedures performed in the United States in 2016. Surg Obes Relat Dis 2018; 14: 259-263
- 6 Barola S, Chen YI, Ngamruengphong S. et al. Technical aspects of endoscopic sleeve gastroplasty. Gastrointest Endosc 2017; 85: 862
- 7 Lopez-Nava G, Galvao MP, Bautista-Castano I. et al. Endoscopic sleeve gastroplasty: How I do it?. Obes Surg 2015; 25: 1534-1538
- 8 Fayad L, Adam A, Schweitzer M. et al. Endoscopic sleeve gastroplasty versus laparoscopic sleeve gastrectomy: a case-matched study. Gastrointest Endosc 2019; 89: 782-788
- 9 Novikov AA, Afaneh C, Saumoy M. et al. Endoscopic sleeve gastroplasty, laparoscopic sleeve gastrectomy, and laparoscopic band for weight loss: How do they compare?. J Gastrointest Surg 2018; 22: 267-273
- 10 Johanns W, Luis W, Janssen J. et al. Argon plasma coagulation (APC) in gastroenterology: experimental and clinical experiences. Eur J Gastroenterol Hepatol 1997; 9: 581-587
- 11 Sagawa T, Takayama T, Oku T. et al. Argon plasma coagulation for successful treatment of early gastric cancer with intramucosal invasion. Gut 2003; 52: 334-339
- 12 Fujishiro M, Kodashima S, Ono S. et al. Submucosal injection of normal saline can prevent unexpected deep thermal injury of Argon plasma coagulation in the in vivo porcine stomach. Gut Liver 2008; 2: 95-98
- 13 Fujishiro M, Yahagi N, Nakamura M. et al. Submucosal injection of normal saline may prevent tissue damage from argon plasma coagulation: an experimental study using resected porcine esophagus, stomach, and colon. Surg Laparosc Endoscop Percutan Tech 2006; 16: 307-311
- 14 Gong EJ, Ahn JY, Jung HY. et al. Effects of argon plasma coagulation on human stomach tissue: An ex vivo study. J Gastroenterol Hepatol 2017; 32: 1040-1045
- 15 Manner H, Neugebauer A, Scharpf M. et al. The tissue effect of argon-plasma coagulation with prior submucosal injection (Hybrid-APC) versus standard APC: A randomized ex-vivo study. United European Gastroenterol J 2014; 2: 383-390
- 16 Kumbhari V, Lehmann S, Schlichting N. et al. Gastric mucosal devitalization is safe and effective in reducing body weight and visceral adiposity in a porcine model. Gastrointest Endosc 2018; 88: 175-184
- 17 Oberbach A, Schlichting N, Heinrich M. et al. Gastric mucosal devitalization reduces adiposity and improves lipid and glucose metabolism in obese rats. Gastrointest Endosc 2018; 87: 288-299 e286
- 18 Watson JP, Bennett MK, Griffin SM. et al. The tissue effect of argon plasma coagulation on esophageal and gastric mucosa. Gastrointest Endosc 2000; 52: 342-345